| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| V E Golimbet, B A Volel', A V Dolzhikov, M I Isaev. [The role of the 5-HTTLPR polymorphism of the serotonin transporter gene in the development of depression in patients with coronary heart disease]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 112. issue 8. 2013-03-12. PMID:23096047. |
[the role of the 5-httlpr polymorphism of the serotonin transporter gene in the development of depression in patients with coronary heart disease]. |
2013-03-12 |
2023-08-12 |
Not clear |
| V E Golimbet, B A Volel', A V Dolzhikov, M I Isaev. [The role of the 5-HTTLPR polymorphism of the serotonin transporter gene in the development of depression in patients with coronary heart disease]. Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova. vol 112. issue 8. 2013-03-12. PMID:23096047. |
serotonin transporter gene polymorphism (5-httlpr) was earlier reported to contribute to the development of depression comorbid to chd. |
2013-03-12 |
2023-08-12 |
Not clear |
| Ian A Mazzetti, Michael J Marcaccio, Odette Boutross-Tadross, Omid Salehian, Catherine Demer. The ace of spades: reverse takotsubo cardiomyopathy in the context of angiographic embolization of recurrent metastatic serotonin-positive neuroendocrine tumour of the pancreas. Case reports in medicine. vol 2013. 2013-03-12. PMID:23476666. |
a 62-year-old woman undergoing embolization of recurrent neuroendocrine tumor, positive for serotonin, developed chest pain and bradycardia with lateral st-segment depression. |
2013-03-12 |
2023-08-12 |
Not clear |
| Francesco Mari, Barbara Gualco, Regina Rensi, Elisabetta Berto. Acute massive pulmonary thromboembolism due to acute intoxication by duloxetine: a case report. Cardiovascular toxicology. vol 12. issue 3. 2013-03-06. PMID:22351288. |
duloxetine (cymbalta) is a potent serotonin norepinephrine reuptake inhibitor used for the management of major depression and pain associated with diabetic peripheral neuropathy. |
2013-03-06 |
2023-08-12 |
Not clear |
| A Mogha, S R Guariglia, P R Debata, G Y Wen, P Banerje. Serotonin 1A receptor-mediated signaling through ERK and PKCα is essential for normal synaptogenesis in neonatal mouse hippocampus. Translational psychiatry. vol 2. 2013-03-04. PMID:22832728. |
aberrant expression of the presynaptic serotonin 1a receptor (5-ht(1a)-r) because of a polymorphism in the 5-ht(1a)-r gene is associated with severe depression in human, whereas its absence up to postnatal day 21 (p21) in the forebrain of mice results in heightened anxiety in adulthood. |
2013-03-04 |
2023-08-12 |
mouse |
| Gabriel D Shapiro, William D Fraser, Jean R Ségui. Emerging risk factors for postpartum depression: serotonin transporter genotype and omega-3 fatty acid status. Canadian journal of psychiatry. Revue canadienne de psychiatrie. vol 57. issue 11. 2013-02-26. PMID:23149286. |
emerging risk factors for postpartum depression: serotonin transporter genotype and omega-3 fatty acid status. |
2013-02-26 |
2023-08-12 |
Not clear |
| Reiji Yoshimura, Taro Kishi, Hikaru Hori, Atsuko Ikenouchi-Sugita, Wakako Umene-Nakano, Asuka Katsuki, Kenji Hayashi, Nakao Iwata, Jun Nakamur. No Association between the Response to the Addition of an Atypical Antipsychotic Drug to an SSRI or SNRI and the BDNF (Val66Met) Polymorphism in Refractory Major Depressive Disorder in Japanese Patients. Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology. vol 10. issue 1. 2013-02-25. PMID:23429762. |
this study examined the association between the brain-derived neurotrophic factor (bdnf) (val66met) polymorphism and the response to the addition of an atypical antipsychotic drug to a selective serotonin reuptake inhibitor (ssri) or serotonin-norepinephrine reuptake inhibitor (snri) in treatment-refractory depression. |
2013-02-25 |
2023-08-12 |
Not clear |
| Saki Shimizu, Yukihiro Ohn. Improving the Treatment of Parkinson's Disease: A Novel Approach by Modulating 5-HT(1A) Receptors. Aging and disease. vol 4. issue 1. 2013-02-21. PMID:23423244. |
thus, 5-ht(1a) agonists improve the various motor disorders associated with dopaminergic deficits, dyskinesia induced by chronic l-dopa treatment, mood disturbances (anxiety and depression) and dopamine agonist-induced emesis. |
2013-02-21 |
2023-08-12 |
Not clear |
| Dorotea Muck-Seler, Nela Pivac, Mirko Diksi. Acute treatment with fluvoxamine elevates rat brain serotonin synthesis in some terminal regions: an autoradiographic study. Nuclear medicine and biology. vol 39. issue 7. 2013-02-12. PMID:22560971. |
a considerable body of evidence indicates the involvement of the neurotransmitter serotonin (5-ht) in the pathogenesis and treatment of depression. |
2013-02-12 |
2023-08-12 |
rat |
| Tim F Oberlander, Anton R Mille. Antidepressant use in children and adolescents: Practice touch points to guide paediatricians. Paediatrics & child health. vol 16. issue 9. 2013-02-07. PMID:23115493. |
where pharmacotherapy is warranted, evidence supports the use of selective serotonin reuptake inhibitor (ssri) antidepressants, particularly fluoxetine, to manage moderate/severe depression. |
2013-02-07 |
2023-08-12 |
Not clear |
| Ante Silić, Dalibor Karlović, Alessandro Serrett. Increased inflammation and lower platelet 5-HT in depression with metabolic syndrome. Journal of affective disorders. vol 141. issue 1. 2013-01-30. PMID:22391518. |
increased inflammation and lower platelet 5-ht in depression with metabolic syndrome. |
2013-01-30 |
2023-08-12 |
Not clear |
| Marina Mitjans, Cristóbal Gastó, Rosa Catalán, Lourdes Fañanás, Bárbara Aria. Genetic variability in the endocannabinoid system and 12-week clinical response to citalopram treatment: the role of the CNR1, CNR2 and FAAH genes. Journal of psychopharmacology (Oxford, England). vol 26. issue 10. 2013-01-30. PMID:22826533. |
first line treatment of major depression is based on selective serotonin re-uptake inhibitors (ssris) that enhance serotonergic neurotransmission by blocking the serotonin transporter. |
2013-01-30 |
2023-08-12 |
Not clear |
| Bengt André. [The serotonin hypothesis is one of several explanatory models for depression and anxiety]. Lakartidningen. vol 109. issue 46. 2013-01-30. PMID:23259219. |
[the serotonin hypothesis is one of several explanatory models for depression and anxiety]. |
2013-01-30 |
2023-08-12 |
Not clear |
| Isaac T Petersen, John E Bates, Jackson A Goodnight, Kenneth A Dodge, Jennifer E Lansford, Gregory S Pettit, Shawn J Latendresse, Danielle M Dic. Interaction between serotonin transporter polymorphism (5-HTTLPR) and stressful life events in adolescents' trajectories of anxious/depressed symptoms. Developmental psychology. vol 48. issue 5. 2013-01-25. PMID:22390669. |
(2003) found an interaction between the serotonin transporter polymorphism gene (5-httlpr) and stressful life events on depression. |
2013-01-25 |
2023-08-12 |
Not clear |
| Isaac T Petersen, John E Bates, Jackson A Goodnight, Kenneth A Dodge, Jennifer E Lansford, Gregory S Pettit, Shawn J Latendresse, Danielle M Dic. Interaction between serotonin transporter polymorphism (5-HTTLPR) and stressful life events in adolescents' trajectories of anxious/depressed symptoms. Developmental psychology. vol 48. issue 5. 2013-01-25. PMID:22390669. |
specifically, adolescents with lower serotonin transcriptional efficiency (te) genotypes whose mothers reported more stressful events were reported to show more anxious/depressed symptoms and greater increases in the development of symptoms of anxiety and depression than were higher te adolescents, particularly at ages 16 and 17. |
2013-01-25 |
2023-08-12 |
Not clear |
| Hui-Chen Su, Ching-Ting Ma, Bu-Chin Yu, Yu-Chieh Chien, Cheng-Chieh Tsai, Wei-Ching Huang, Chiou-Feng Lin, Yeu-Hui Chuang, Kung-Chia Young, Jieh-Neng Wang, Chiung-Wen Tsa. Glycogen synthase kinase-3β regulates anti-inflammatory property of fluoxetine. International immunopharmacology. vol 14. issue 2. 2013-01-24. PMID:22749848. |
a selective serotonin reuptake inhibitor fluoxetine not only is widely used in the treatment of depression but also has an anti-inflammatory property. |
2013-01-24 |
2023-08-12 |
mouse |
| George I Papakostas, Hua Fan, Enrico Tedeschin. Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 22. issue 5. 2013-01-22. PMID:22099607. |
severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors. |
2013-01-22 |
2023-08-12 |
Not clear |
| George I Papakostas, Hua Fan, Enrico Tedeschin. Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 22. issue 5. 2013-01-22. PMID:22099607. |
anxious depression was not found to serve as a treatment moderator for selective serotonin reuptake inhibitor therapy versus placebo. |
2013-01-22 |
2023-08-12 |
Not clear |
| George I Papakostas, Hua Fan, Enrico Tedeschin. Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 22. issue 5. 2013-01-22. PMID:22099607. |
however, when patients with severe depression were analyzed separately, anxious depression significantly influenced the relative degree of symptom reduction with selective serotonin reuptake inhibitors versus placebo (p=0.0094). |
2013-01-22 |
2023-08-12 |
Not clear |
| George I Papakostas, Hua Fan, Enrico Tedeschin. Severe and anxious depression: combining definitions of clinical sub-types to identify patients differentially responsive to selective serotonin reuptake inhibitors. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 22. issue 5. 2013-01-22. PMID:22099607. |
subdividing patients with severe major depressive disorder into those with versus without anxious depression results in the characterization of sub-types that are particularly "responsive" (severe non-anxious) and "unresponsive" (severe anxious) to selective serotonin reuptake inhibitor therapy (relative to placebo). |
2013-01-22 |
2023-08-12 |
Not clear |